Weight Management Program
Match the right therapy to each member — then support and monitor them closely on it. A pre-therapy genomic panel paired with guideline-based clinical monitoring, delivered as one coordinated experience.
The number-one reason members quit isn't the drug — it's the side effects
Early discontinuation is the most common failure mode in GLP-1 programs, and nausea or vomiting during dose escalation is the most common reason members stop — often after the cost has already been spent. This program is built to flag elevated-risk members before the first dose, so titration pace and support can be planned proactively rather than reactively.
Genomic stratification, then guideline-based monitoring
Part 1 · Genomic Stratification
A pre-therapy genotyping panel returning an efficacy sub-score and a GI-tolerability sub-score. Done once, before the first dose, to help set drug choice, dose pace, and support. Wellness-grade — a one-time buccal swab; the result is a genotype and does not change over time.
Part 2 · Clinical Monitoring
Baseline and serial labs — A1c, comprehensive metabolic panel, CBC, lipid panel, and TSH — through titration and maintenance. Established standard of care, billed through normal channels like any other laboratory testing.
Five steps, coordinated from enrollment
Enroll
Genomic panel and baseline labs ordered together.
Baseline Testing
Buccal swab for genomics; blood draw for monitoring labs.
Report
Two sub-scores, plus baseline lab results.
Titrate
Dose pace and support set with the genotype in mind.
Monitor & Maintain
Serial labs on a defined cadence through maintenance.
Built for clinicians, members, and payers alike
For Clinicians
Decision support at the point of prescribing. Enrollment yields genotype-informed guidance on drug choice, titration pace, and support intensity — alongside a full baseline lab panel with defined renal, hepatic, glycemic, and thyroid follow-up. Every auto-generated therapy note is clearly marked for provider review and is not a substitute for clinical guidelines or judgment.
For Individuals
One appointment, a plan informed by your own biology, and proactive check-ins designed to catch issues early. This is a wellness-grade test meant to support a conversation with your care team, not a diagnosis or a guarantee of how you'll respond — your provider makes the final call on therapy.
For Payers & Employers
Early discontinuation is a top driver of wasted GLP-1 program spend. This program targets that directly with evidence-tiered genomic stratification, while clinical monitoring is billed through standard channels like any other lab work — the wellness-grade genomic panel is offered as a separate, clearly identified elective service, not bundled into a coverage claim.
10 markers across 5 gene modules
| Module | Genes | Markers | Evidence Tier |
|---|---|---|---|
| Efficacy — GLP-1 Receptor Agonists | GLP1R | 3 | Moderate–Emerging |
| Tolerability — Gastrointestinal | GLP1R, GIPR | 2 | Strong (GWAS) |
| DPP-4 Inhibitor Specific | TCF7L2, CTRB1/2 | 2 | Moderate |
| Glycemic Response (Signaling) | ARRB1 | 1 | Moderate |
| Obesity Context | MC4R, FTO | 2 | Contextual |
This panel tests drug-target and incretin-pathway biology (GLP1R, GIPR, and related genes) — not drug metabolism. Injectable GLP-1 receptor agonists are peptides and are not processed by the liver's CYP450 enzymes the way many small-molecule drugs are, so classic "metabolizer" genes don't apply here. Evidence tiers: Strong (GWAS) = genome-wide significant and replicated · Moderate = replicated across more than one cohort · Emerging = early, biologically plausible, not yet replicated · Contextual = informs baseline risk, not drug response.
Two plain-language scores, not a wall of raw genotypes
Separate efficacy and GI-tolerability sub-scores translate directly into titration pace and support intensity — with every medication on the market compared against that person's own genotype, not a general ranking.
Response Profile Summary (Illustrative)
Illustrative example only. Scores, genotypes, and the medication comparison that follows in the full report are specific to each individual's own genotype and are not a general ranking of one drug over another for everyone.
Every report also includes a full medication comparison (injectable and oral GLP-1 options, plus DPP-4 inhibitors as a weight-neutral glycemic alternative), a plain-language explanation of each finding with its evidence tier, lifestyle guidance to support GI tolerability during titration, and a therapy-guidance section that is clearly marked as auto-generated decision support requiring provider review before prescribing.
Guideline-based labs, on a defined cadence
| Aspect | Details |
|---|---|
| Baseline & Serial Labs | A1c · Comprehensive metabolic panel · CBC · Lipid panel · TSH |
| Cadence | Every 3 months in year one (titration), then every 6–12 months in maintenance |
| Event-Driven | Metabolic panel during any illness with fluid loss, per 2024 KDIGO renal guidance |
| Liver, at No Extra Draw | FIB-4 fibrosis score calculated from labs already drawn (age, AST, ALT, platelets), per AASLD guidance |
Monitoring supports safer care and earlier detection of problems; it does not eliminate the inherent risks of GLP-1 medication.
Built to be read, not decoded
Two plain-language scores
Efficacy and GI-tolerability, not raw genotypes to decode.
Full medication comparison
Genotype applied to every option on the market, injectable and oral.
Evidence you can check
Every marker carries an evidence tier and a source citation.
Lifestyle & adjunct guidance
Practical, non-pharmacological support for GI tolerability during titration.